<div id="readability-page-1"><p>Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $34.00 and last traded at $33.91, with a volume of 17346 shares changing hands. The stock had previously closed at $32.31.</p><div><p><span></span><span>Get <strong>Viridian Therapeutics</strong> alerts:</span></p></div><h2>Analyst Ratings Changes</h2><p>Several research analysts recently commented on the stock. William Blair began coverage on shares of Viridian Therapeutics in a report on Wednesday, December 3rd. They issued an &#34;outperform&#34; rating on the stock. Wedbush lifted their price objective on Viridian Therapeutics from $42.00 to $47.00 and gave the stock an &#34;outperform&#34; rating in a research note on Wednesday, December 10th. Royal Bank Of Canada boosted their price objective on Viridian Therapeutics from $41.00 to $45.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, November 6th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Viridian Therapeutics in a report on Wednesday, October 8th. Finally, Jefferies Financial Group started coverage on Viridian Therapeutics in a research report on Monday, August 25th. They issued a &#34;buy&#34; rating and a $44.00 price target on the stock. Eleven equities research analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has issued  a Sell rating to the company's stock. According to data from MarketBeat.com, the stock  has an average rating of &#34;Moderate Buy&#34; and an average price target of $41.08.</p><p><b>Read Our Latest Stock Analysis on VRDN</b></p><h2>Viridian Therapeutics Trading Up 4.3%</h2><p>The company's fifty day moving average price is $26.78 and its two-hundred day moving average price is $20.64. The company has a quick ratio of 11.28, a current ratio of 11.28 and a debt-to-equity ratio of 0.07. The company has a market cap of $3.21 billion, a price-to-earnings ratio of -11.20 and a beta of 0.86. </p><p>Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.82) by $0.48. The company had revenue of $70.57 million during the quarter, compared to analyst estimates of $16.21 million. Viridian Therapeutics had a negative return on equity of 78.50% and a negative net margin of 426.58%.The firm's revenue for the quarter was up 81993.0% on a year-over-year basis.  Research analysts expect that  Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year. </p><h2>Insider Buying and Selling</h2><p>In other news, Director Fairmount Funds Management Llc purchased 454,545 shares of the firm's stock in a transaction that occurred on Thursday, October 23rd. The shares were acquired at an average price of $22.00 per share, for a total transaction of $9,999,990.00. Following the completion of the acquisition, the director directly owned 3,914,458 shares in the company, valued at approximately $86,118,076. The trade was a 13.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink. Insiders own  0.65% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Several hedge funds have recently modified their holdings of VRDN. Corton Capital Inc. acquired a new stake in  Viridian Therapeutics during the 2nd quarter worth $248,000.  Moody Aldrich Partners LLC grew its stake in shares of  Viridian Therapeutics by 54.2% during the second quarter. Moody Aldrich Partners LLC now owns 89,164 shares of the company's stock worth $1,247,000 after purchasing an additional 31,323 shares during the period.  Hsbc Holdings PLC bought a new stake in  Viridian Therapeutics in the first quarter valued at about $526,000.  Raymond James Financial Inc. lifted its stake in  Viridian Therapeutics by 1.4% in the first quarter. Raymond James Financial Inc. now owns 318,240 shares of the company's stock valued at $4,290,000 after buying an additional 4,453 shares during the period.  Finally, J. Safra Sarasin Holding AG raised its position in shares of  Viridian Therapeutics by 135.5% in the 2nd quarter. J. Safra Sarasin Holding AG now owns 171,119 shares of the company's stock valued at $2,392,000 after acquiring an additional 98,447 shares during the period. </p><h2>Viridian Therapeutics Company Profile</h2> (Get Free Report)<p>Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Viridian Therapeutics</li><li>CD Calculator: Certificate of Deposit Calculator </li><li>3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains</li><li>Insider Trading - What You Need to Know</li><li>GOOGL's Unstoppable Momentum Drives Price Targets to Record Highs</li><li>What is the Shanghai Stock Exchange Composite Index?</li><li>3 Underrated Robotics Stocks Poised for Huge Gains</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Viridian Therapeutics Right Now?</h2><p>Before you consider Viridian Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.</p><p>While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VRDN

<p>Viridian Therapeutics (NASDAQ:VRDN) reached a new 52-week high, trading as high as $34.00. Analysts have given the stock an average rating of 'Moderate Buy' with a price target of $41.08. The company reported better-than-expected earnings, with revenue significantly up year-over-year. Insider and institutional activities show increased interest in the stock. Viridian's product pipeline includes treatments for thyroid eye disease.</p>

Viridian Therapeutics (NASDAQ:VRDN) Sets New 52-Week High - Should You Buy?